BOK Financial Private Wealth Inc. Lowers Holdings in Stryker Co. (NYSE:SYK)

BOK Financial Private Wealth Inc. lessened its position in Stryker Co. (NYSE:SYK - Free Report) by 13.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,466 shares of the medical technology company's stock after selling 701 shares during the quarter. BOK Financial Private Wealth Inc.'s holdings in Stryker were worth $1,612,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp raised its stake in Stryker by 2.2% during the third quarter. State Street Corp now owns 14,582,959 shares of the medical technology company's stock valued at $5,279,788,000 after buying an additional 316,404 shares during the last quarter. FMR LLC raised its stake in Stryker by 3.0% during the third quarter. FMR LLC now owns 7,306,994 shares of the medical technology company's stock valued at $2,639,725,000 after buying an additional 215,782 shares during the last quarter. Geode Capital Management LLC raised its stake in Stryker by 2.5% during the third quarter. Geode Capital Management LLC now owns 6,905,126 shares of the medical technology company's stock valued at $2,484,893,000 after buying an additional 165,490 shares during the last quarter. Parnassus Investments LLC purchased a new position in Stryker during the third quarter valued at $762,798,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Stryker by 2.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,985,045 shares of the medical technology company's stock valued at $714,715,000 after buying an additional 48,819 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Remove Ads

Insider Activity at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. JMP Securities reiterated a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. Royal Bank of Canada lifted their target price on Stryker from $425.00 to $435.00 and gave the stock an "outperform" rating in a report on Wednesday, January 29th. Morgan Stanley raised Stryker from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. StockNews.com lowered Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Finally, The Goldman Sachs Group set a $422.00 target price on Stryker in a report on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $421.90.

Stryker Stock Performance

NYSE SYK traded down $1.77 on Wednesday, hitting $363.52. 1,559,119 shares of the company traded hands, compared to its average volume of 1,218,285. The company has a market capitalization of $138.71 billion, a price-to-earnings ratio of 46.85, a P/E/G ratio of 2.93 and a beta of 0.95. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The business's 50 day moving average price is $382.76 and its 200-day moving average price is $373.33. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the firm earned $3.46 EPS. Equities analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.92%. Stryker's dividend payout ratio (DPR) is presently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.